Bivalent HPV Recombinant Vaccine (Cervarix) for the Prevention of Cervical Cancer

Bivalent HPV Recombinant Vaccine (Cervarix) for the Prevention of Cervical Cancer

The bivalent human papillomavirus (HPV) recombinant vaccine (Cervarix) is the second vaccine to be approved in the US for the prevention of cervical cancer, cervical adenocarcinoma in situ, and cervical intraepithelial neoplasia caused by HPV types 16 and 18. Unlike the quadrivalent HPV vaccine (Gar...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American family physician 2010-12, Vol.82 (12), p.57
Hauptverfasser: Schauner, Stephanie, Lyon, Corey
Format: Artikel
Sprache:eng
Schlagworte:
Cervical cancer
Disease prevention
Effectiveness
Human papillomavirus
Safety
Vaccines
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The bivalent human papillomavirus (HPV) recombinant vaccine (Cervarix) is the second vaccine to be approved in the US for the prevention of cervical cancer, cervical adenocarcinoma in situ, and cervical intraepithelial neoplasia caused by HPV types 16 and 18. Unlike the quadrivalent HPV vaccine (Gardasil), Cervarix doesn't provide protection against HPV types 6 and 11, which are responsible for 90% of genital warts in males and females. Here, Schauner and Lyon look at the safety, tolerability, and effectiveness of Cervarix.
ISSN:0002-838X